Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

By C. Robert, Antoni Ribas, J. Wolchok, F. Hodi, O. Hamid, R. F. Kefford, J. Weber, A. Joshua, W. Hwu, T. Gangadhar and 15 more. The Lancet, 2014

1,629 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/26c07f894475206450040042c76f3e50e4d7860c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Peter W. Laird
2. S. Baylin
3. Eric S. Lander
4. Manel Esteller
5. Timothy Triche
6. Katherine A. Hoadley
7. J. Herman
8. J. Wolchok

In Oncology

1. J. Wolchok
2. M. Postow
3. C. Robert
4. Ton N. Schumacher
5. F. Hodi
6. K. Kerr
7. D. Thommen
8. Georgina V. Long

Citations in the corpus

• Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis (2017, background): “5%]) (Figure4).(18,19,21,23,31,32,36,42-46)Comparedwithpatientswhoreceived ipilimumab,patientswho receivedPD-1 inhibitorswere significantly less likely to experience any grade hypophysitis (OR, 0.”
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. (2016, background): “Pancreatitis has been reported infrequently in studies of anti-CTLA-4 [87] and antiPD-1 agents [7, 10, 28]; therefore, clinical suspicion of pancreatitis should prompt assessment of amylase and lipase.”
• Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. (2015, neutral): “Pembrolizumab has shown similar efficacy and safety compared with nivolumab in a phase I clinical trial in advanced melanoma (NCT01295827) (48, 49) and is now an FDA-approved second-line drug for the treatment of melanoma (40).”
• Genomic Classification of Cutaneous Melanoma (2015, background): “The lack of a genomic correlation with outcome provides a plausible molecular explanation for the lack of observed preferential antitumor responses in clinical trials employing immune checkpoint blockade, at least in relation to BRAF status (Ascierto et al., 2014; Robert et al., 2014).”
• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017, background): “Diarrhoea and colitis are more frequent with anti-CTLA4 agents than with either nivolumab or pembrolizumab, with grade 3 to 4 AEs occurring in 1%–2% of cases [2, 50].”